Renovis surgical receives FDA clearance for 3D-printed posterior lumbar interbody fusion systems

Renovis Surgical Technologies (a US- based implants manufacturing company) announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market posterior lumbar Tesera porous titanium interbody fusion systems.

These systems feature implants for direct posterior (PLIF) or transforaminal (TLIF) approaches in both straight and curved options. Multiple heights, widths and lengths are available to better fit varying patient anatomies. All Tesera implants are produced through additive manufacturing (3D printing) and the company's proprietary Tesera Trabecular Technology, a highly porous structure that allows for bone attachment to implant surfaces and the potential for biologic fixation deep into the pore structure for long-term stability.

This is the fifth product group featuring the Tesera porous titanium structure for which Renovis Surgical has received FDA clearance.